Companies › Immatics US
3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMA203 (anzutresgene autoleucel, anzu-cel) PRAME-redirected CAR-T cell therapy | PRAME | Phase 3 | Melanoma, Cutaneous Malignant; Refractory Cancer; Cutaneous Melanoma | Jan 2028 |
| IMA203CD8 ACTengine autologous T-cell therapy targeting PRAME | – | Phase 1 | Refractory Cancer | Dec 2028 |
| mRNA-4203 mRNA vaccine (adjunctive immunotherapy) | – | Phase 1 | Cutaneous Melanoma | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06743126 | IMA203 (anzutresgene autoleucel, anzu-cel) | Phase 3 | Melanoma, Cutaneous Malignant | Oncology | Jan 2028 |
| NCT03686124 | IMA203 (anzutresgene autoleucel, anzu-cel) | Phase 1 | Refractory Cancer | Oncology | Dec 2028 |
| NCT03686124 | IMA203CD8 | Phase 1 | Refractory Cancer | Oncology | Dec 2028 |
| NCT06946225 | mRNA-4203 | Phase 1 | Cutaneous Melanoma | Oncology | Aug 2029 |
| NCT06946225 | IMA203 (anzutresgene autoleucel, anzu-cel) | Phase 1 | Cutaneous Melanoma | Oncology | Aug 2029 |
Takara Bio Tesaro Immunocore HRYZ Biotech Erasca
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.